1/1
2 files

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

media
posted on 13.04.2021, 14:27 by Adis journals on behalf of, Philip J. Mease, Apinya Lertratanakul, Kim A. Papp, Filip E. van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro W. Keiserman, Xianwei Bu, Liang Chen, Reva M. McCaskill, Patrick Zueger, Erin L. McDearmon-Blondell, Aileen L. Pangan, William Tillett

Article full text


The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.

History